Back To All
View in

French drugmaker Sanofi set to buy IPOX® 100 U.S. holding Bioverativ at 63% premium

Bioverativ is a portfolio holding in a number of IPOX® Indexes, including the IPOX® Composite U.S. (IPXC) and IPOX® 100 U.S. Index (IPXO).

The IPOX® 100 U.S. Index (IPXO) serves as the underlying benchmark for the USD billion 1.05, 5-star (10 years) First Trust U.S. Equity Opportunity Fund (ticker: FPX), an exchange traded fund listed on the New York Stock Exchange (NYSE). Since launch in 2006, the ETF delivered a total return of +295.61% vs. 177.40% for the ETF tied to the S&P 500 (SPY), yardstick for U.S. stocks.